Dr Reddys

Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada. The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement. Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added. "The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr Reddy's CEO Erez Israeli said. He further said:"With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients." The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said. "As GLP-1

Dr Reddy's-Nestle Health Science JV launched Celevida GLP+ to support nutrition and muscle health among patients on GLP-1 and GIP therapies

Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Court allows Dr Reddy's 30 days to clear stock, after which unsold Olymviq doses will be supplied to government hospitals in presence of Novo Nordisk representative

Among others Dr. Reddy's, Apollo Hospitals, M&M Finance, Muthoot Finance, Tata Power, Balrampur Chini and Sammaan Capital soared up to 20% from recent lows to cross the long-term average, shows data.

The Delhi High Court has upheld an order permitting Dr Reddy's Laboratories to manufacture semaglutide in India solely for export, rejecting Novo Nordisk's appeal in the ongoing patent dispute

Stocks to Watch today, February 25, 2026: Schaeffler India, Aditya Infotech, RVL are among few stocks that will be in focus

Wegovy's monthly price in India ranges from ₹10,850 ($119.65) for the lowest 0.25 mg dose to ₹16,400 for the highest 2.4 mg dose

Analysts at Choice Broking expects Dr Reddy's Laboratories stock to gain up to 15.5%, and test ₹1,465 levels on the upside in the medium-term given the favourable structure on the weekly chart.

Ozempic is also used off-label for weight loss due to its appetite-suppressing effects

Stocks to watch on Thursday, January 22, 2026: KEI Industries, Bajaj Consumer Care, PNB Housing Finance and Jindal Stainless are among other key stocks to track today

Dr Reddy's Laboratories reported a sharp fall in December-quarter profit as declining Lenalidomide sales in the US weighed on earnings, even as India revenues and branded businesses remained resilient

Q3FY26 company results: Firms including Bank of India, Jindal Stainless, PNB Housing Finance, and Tata Communications are also to release their October-December earnings reports today

Stocks to watch today, Wednesday, January 21, 2026: Cyient DLM, Shoppers Stop, HDFC Bank, Tata Steel, and Vikram Solar are among other key stocks to track today.

Novo Nordisk's appeal was listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

The Delhi High Court refused to stop an earlier order that lets Dr Reddy's make Semaglutide in India only for export, saying Novo Nordisk's patent challenge needs a full hearing before any decision

Ruling enables production for non-patented markets but bars India sales till 2026; experts say it may shape future drug access cases

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.